SCHEMBL1691333

SCHEMBL1691333

Fc1ccc(-c2cn3cc(Cl)ccc3n2)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.54
NPC1 O15118 3/20 0.54
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 6/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
NR4A2 P43354 2/20 0.46
APP P05067 1/20 0.46
HPGD P15428 2/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CYP11B1 P15538 2/20 0.44
CYP11B2 P19099 2/20 0.44
CLK1 P49759 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16270663 0.84 NPC1 (0.53) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL13269722 0.83 NR4A2 (0.63) RAB9ANPC1ALDH1A1NR4A2APP
SCHEMBL1691248 0.82 NPC1 (0.48) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL1691855 0.81 FFAR1 (0.42) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL1691364 0.78 RAB9A (0.60) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL13325716 0.78 RAB9A (0.81) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL964317 0.78 RAB9A (0.63) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL1691361 0.77 DYRK1A (0.49) RAB9ANPC1KDM4EALDH1A1MAPT
Hydrochloric Acid SCHEMBL8874207 0.77 RAB9A (0.61) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL2063035 0.75 NR4A2 (0.72) RAB9ANPC1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS BIOVITRUM AB (PUBL) (SE) 2015-08-27 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed
EP-2376490-A1 IMIDAZOPYRIDINE COMPOUNDS Proximagen Limited (GB) 2011-10-19 EP disclosed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010188-A1 Imidazopyridine Compounds SSB, MIF, IDO1 RAB9A 3798/4885NPC1 1153/4885KDM4E 2671/4885
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS SSB, MIF, IDO1 RAB9A 3798/4885NPC1 1153/4885KDM4E 2671/4885
US-20140206662-A1 Imidazopyridine Compounds SSB, NFKBIA, TPMT RAB9A 3886/4885NPC1 2286/4885KDM4E 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.